Oral supplementation of propionyl-l-carnitine reduces body weight and hyperinsulinaemia in obese Zucker rats

British Journal of Nutrition

Volumn 102, Issue 8, 2009, Pages 1145-1153

  Mingorance, Carmen ^a   Gonzalez Del Pozo, Maria ^a   Dolores Herrera, Maria ^a   Alvarez De Sotomayor, Maria ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Insulin resistance; Metabolic syndrome; Obese Zucker rats; Propionyl l carnitine

Indexed keywords

ACETYLCHOLINE; ADIPONECTIN; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PROPIONYLCARNITINE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY CONSTRICTION; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FATTY ACID BLOOD LEVEL; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HEART RATE; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPOPROTEIN BLOOD LEVEL; LIVER WEIGHT; MESENTERIC ARTERY; NONHUMAN; OBESITY; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION; ZUCKER RAT;

ANIMALS; CARNITINE; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; ENDOTHELIUM, VASCULAR; GLUCOSE TOLERANCE TEST; HEMODYNAMICS; HYPERINSULINISM; INSULIN RESISTANCE; LIPIDS; METABOLIC SYNDROME X; OBESITY; RATS; RATS, ZUCKER; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS; WEIGHT GAIN;

ANIMALIA; RATTUS;

EID: 73749083758     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114509389230     Document Type: Article

References (29)

1. Wiseman LR & Brogden RN (1998) Propionyl-L-carnitine. Drugs Aging 12, 243-248.
2. Binienda Z & Virmani A (2003) The mitochondriotropic effects of L-carnitine and its esters in the central nervous system. Curr Med Chem 3, 275-282.
3. Siliprandi N, Di Lisa F & Menabò R (1991) Propionyl- Lcarnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 5, 11-15.
4. Alberti KG, Zimmet P, Shaw J, et al. (2005) The metabolic syndrome - a new worldwide definition. Lancet 366, 1059-1062. (Pubitemid 41338752)
5. Avogaro A & de Kreutzenberg SV (2005) Mechanisms of endothelial dysfunction in obesity. Clin Chim Acta 360, 9-26.
6. Meigs JB, Larson MG, Fox CS, et al. (2007) Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care 30, 2529-2535.
7. Furukawa S, Fujita T, Shimabukuro M, et al. (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114, 1752-1761.
8. Kim JA, Montagnani M, Koh KK, et al. (2006) Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113, 1888-1904.
9. Bueno R, Alvarez de Sotomayor M, Perez-Guerrero C, et al. (2005) L-Carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: different participation of NO and COX-products. Life Sci 77, 2082-2097.
10. Alvarez de Sotomayor M, Bueno R, Pérez-Guerrero C, et al. (2007) Effect of L-carnitine and propionyl-L-carnitine on endothelial function of small mesenteric arteries from SHR. J Vasc Res 44, 354-364.
11. de Sotomayor MA, Mingorance C, Rodriguez-Rodriguez R, et al. (2007) L-Carnitine and its propionate: improvement of endothelial function in SHR through superoxide dismutasedependent mechanisms. Free Radic Res 41, 884-891.
12. Santo SS, Sergio N, Luigi DP, et al. (2006) Effect of PLC on functional parameters and oxidative profile in type 2 diabetesassociated PAD. Diabetes Res Clin Pract 72, 231-237.
13. Lango R, Smoleński RT, Rogowski J, et al. (2005) Propionyl-Lcarnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients. Cardiovasc Drugs Ther 19, 267-275.
14. Matthews DR, Hosker JP, Rudenski AS, et al. (1985) Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419.
15. Zucker LM & Antoniades HN (1972) Insulin and obesity in the Zucker genetically obese rat 'fatty'. Endocrinology 90, 1320-1330.
16. Arvola P, Wu X, Kahonen M, et al. (1999) Exercise enhances vasorelaxation in experimental obesity associated hypertension. Cardiovasc Res 43, 992-1002.
17. He Y & Macleod KM (2008) Modulation of noradrenalineinduced vasoconstriction in isolated perfused mesenteric arterial beds from obese Zucker rats in the presence and absence of insulin. Can J Physiol Pharmacol 80, 171-179.
18. Subramanian R & Macleod KM (2003) Age-dependent changes in blood pressure and arterial reactivity in obese Zucker rats. Eur J Pharmacol 477, 143-152.
19. Galisteo M, Sanchez M, Vera R, et al. (2005) A diet supplemented with husks of Plantago ovata reduces the development of endothelial dysfunction, hypertension, and obesity by affecting adiponectin and TNF-a in obese Zucker rats. J Nutr 135, 2399-2404.
20. Frisbee JC & Delp MD (2006) Vascular function in the metabolic syndrome and the effects on skeletal muscle perfusion: lessons from the obese Zucker rat. Essays Biochem 42, 145-161.
21. Goldstein BJ, Scalia RG & Ma XL (2009) Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 6, 27-35.
22. Gómez-Amores L, Mate A, Revilla E, et al. (2006) Antioxidant activity of propionyl-L-carnitine in liver and heart of spontaneously hypertensive rats. Life Sci 78, 1945-1952.
23. Calo LA, Pagnin E, Davis PA, et al. (2006) Antioxidant effect of L-carnitine and its short chain esters. Relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol 107, 54-60.
24. Loffredo L, Pignatelli P & Cangemi R (2006) Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect of an antioxidant treatment. J Vasc Surg 44, 525-530.
25. Hiatt WM, Regensteiner JG, Creager MA, et al. (2001) Propionyl- L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 110, 616-622.
26. Ferrari R, Merli E, Cicchitelli G, et al. (2004) Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular disease: a review. Ann NY Acad Sci 1033, 79-91.
27. Broderick TL, Driedzic W & Paulson DJ (2000) Propionyl-Lcarnitine effects on postischemic recovery of heart function and substrate oxidation in the diabetic rat. Mol Cell Biochem 206, 151-157.
28. Power RA, Hulver MW, Zhang JY, et al. (2007) Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia 50, 824-832.
29. Durham HA & Truett GE (2006) Development of insulin resistance and hyperphagia in Zucker fatty rats. Am J Physiol Regul Integr Comp Physiol 290, R652-R658.